Retracted and republished from: "The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs".
mBio
; 15(5): e0017524, 2024 05 08.
Article
in En
| MEDLINE
| ID: mdl-38551343
ABSTRACT
Influenza viruses (IVs) threaten global human health due to the high morbidity, infection, and mortality rates. Currently, the influenza drugs recommended by the Food and Drug Administration are oseltamivir, zanamivir, peramivir, and baloxavir marboxil. These recommended antivirals are currently effective for major subtypes of IVs as the compounds target conserved domains in neuraminidase or polymerase acidic (PA) protein. However, this trend may gradually change due to the selection of antiviral drugs and the natural evolution of IVs. Therefore, there is an urgent need to develop drugs related to the treatment of influenza to deal with the next pandemic. Here, we summarized the cutting-edge research in mechanism of action, inhibitory activity, and clinical efficacy of drugs that have been approved and drugs that are still in clinical trials for influenza treatment. We hope this review will provide up-to-date and comprehensive information on influenza antivirals and generate hypotheses for screens and development of new broad-spectrum influenza drugs in the near future.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Clinical Trials as Topic
/
Influenza, Human
/
Drug Development
Limits:
Humans
Language:
En
Journal:
MBio
Year:
2024
Document type:
Article
Affiliation country:
China